current
data
indic
bronchiol
diagnosi
compris
one
condit
clinic
pathophysiolog
even
genet
three
main
cluster
patient
identifi
among
children
suffer
sever
bronchiol
first
wheez
episod
respiratori
syncyti
viru
rsv
induc
bronchiol
character
young
age
patient
mechan
obstruct
airway
due
bronchiol
often
describ
virusinduc
inflamm
small
bronchiol
surround
tissu
accord
differ
guidelin
upper
age
limit
vari
month
month
prefer
mani
european
countri
year
use
unit
state
clinic
bronchiol
character
expiratori
breath
difficulti
infant
symptom
includ
cough
tachypnea
hyperinfl
chest
retract
widespread
crackl
wheez
wheez
gener
mandatori
criterion
instead
descript
term
defin
whistl
sound
expir
often
accompani
dyspnea
caus
obstruct
level
lower
airway
howev
bilateralpolyphon
inflamm
probabl
bronchiol
present
huge
clinic
burden
depend
definit
preval
bronchiol
first
second
year
life
time
overal
risk
recurr
wheez
asthma
schoolag
school
year
howev
patient
characterist
risk
asthma
strongli
vari
insid
bronchiol
cohort
thu
reveal
differ
diseas
entiti
markedli
high
risk
subsequ
asthma
develop
end
propos
differenti
bronchiol
subtyp
specif
virus
broad
inclus
children
extend
upper
age
limit
month
year
recent
data
clearli
indic
two
major
viral
caus
bronchiol
respiratori
syncyti
viru
rsv
rhinoviru
rv
distinct
genet
pathogenet
mechan
clinic
characterist
respons
treatment
regard
shortand
longterm
outcom
thu
gener
bronchiol
diagnosi
revisit
identif
differ
virus
associ
sever
bronchiol
improv
understand
diseas
open
avenu
precis
medicin
definit
bronchiol
viru
infect
pcr
diagnost
reach
viru
detect
rate
sever
bronchiol
rsv
import
caus
agent
bronchiol
infanc
detect
hospit
bronchiol
case
figur
rv
second
common
viral
agent
bronchiol
infanc
start
domin
viru
detect
month
figur
next
common
virus
connect
bronchiol
human
bocaviru
human
metapneumoviru
follow
parainfluenza
viru
adenoviru
coronaviru
influenza
viru
figur
viru
coinfect
mostli
rsv
rv
occur
sever
case
report
clinic
signific
inconclus
respiratori
syncyti
viru
belong
pneumoviru
genu
paramyxovirida
famili
envelop
singlestrand
rna
viru
two
antigen
differ
b
subtyp
genotyp
respect
although
sever
reinfect
report
young
children
gener
mild
main
risk
factor
rsv
bronchiol
includ
prematur
chronic
lung
diseas
low
lung
function
congenit
heart
diseas
underli
medic
condit
young
age
month
age
condit
excess
mucu
airway
problemat
well
defici
interferon
respons
rhinoviru
belong
enteroviru
genu
picornavirida
famili
nonenvelop
singlestrand
rna
viru
compris
genet
divers
group
virus
three
distinct
subgroup
b
c
consist
genotyp
respect
antigen
divers
present
major
challeng
establish
protect
immun
develop
vaccin
risk
factor
rvinduc
bronchiol
includ
helper
polar
immun
respons
allergen
exposur
impair
epitheli
barrier
defici
interferon
respons
diminish
lung
function
acut
bronchiol
clinic
diagnosi
requir
epidemiolog
virolog
data
infant
day
runni
nose
fever
cough
typic
preced
sign
lower
respiratori
distress
nasal
flare
tachypnea
subcost
recess
figur
case
respiratori
crackl
suggest
rv
etiolog
wherea
bilater
wheez
suggest
rv
etiolog
plethora
respiratori
sound
also
heard
infant
bronchiol
present
mild
clinic
form
usual
resolv
week
safe
manag
home
wellinstruct
parent
adequ
inform
concern
sign
deterior
includ
low
oxygen
satur
need
urgent
transfer
hospit
critic
import
still
clear
whether
type
viru
detect
nasopharynx
could
determin
degre
sever
infect
often
rsv
infect
link
sever
nonwheezi
bronchiol
need
possibl
intens
care
unit
admiss
prolong
durat
stay
howev
greek
casecontrol
studi
show
rv
detect
upper
airway
could
strongli
associ
episod
increas
sever
virus
less
often
link
sever
ill
sinc
earli
sever
effort
toward
develop
clinic
sever
score
tool
bronchiol
sever
score
tool
tal
modifi
tal
score
tool
sever
instrument
valid
use
research
clinic
manag
set
howev
tool
develop
assess
clinic
sever
qualiti
life
paramet
children
apart
use
mere
clinic
sever
score
attempt
made
order
cluster
acut
bronchiol
phenotyp
four
phenotyp
introduc
two
larg
multicent
studi
profil
character
rv
etiolog
histori
wheez
wheez
present
eczema
older
age
patient
profil
b
rsv
etiolog
wheez
present
histori
wheez
eczema
profil
c
sever
ill
group
longer
hospit
stay
high
probabl
rsv
infect
intens
care
unit
treatment
profil
least
sever
ill
includ
nonwheez
children
shorter
length
hospit
heterogen
appar
clinic
profil
patient
highlight
need
person
approach
diagnost
manag
condit
rsv
rv
common
environment
exposur
sever
bronchiol
rel
rare
therefor
seem
like
host
factor
genet
import
risk
factor
well
unfortun
current
understand
genet
risk
factor
bronchiol
limit
twin
studi
estim
herit
rsv
respiratori
syncyti
virusinduc
bronchiol
rhinovirusinduc
first
wheez
episod
main
cluster
sever
bronchiol
less
children
import
distinguish
overlap
patient
group
sinc
differ
clinic
pathophysiolog
genet
like
respond
differ
treatment
first
episod
sever
bronchiol
appear
critic
event
opportun
design
secondari
prevent
strategi
asthma
bronchiol
wherea
estim
herit
asthma
present
genomewid
associ
studi
gwa
includ
replic
identifi
loci
prefer
method
gene
discoveri
one
rel
small
gwa
bronchiol
perform
without
genomewid
signific
find
number
suscept
gene
suggest
candid
gene
studi
studi
focus
rsv
bronchiol
report
associ
includ
gene
relat
immun
regul
surfact
protein
sever
gene
also
associ
asthma
suggest
associ
rsv
bronchiol
later
asthma
develop
might
partli
explain
share
genet
nevertheless
bronchiol
poorli
defin
highli
heterogen
diseas
entiti
variabl
clinic
present
age
infect
trigger
factor
well
underli
genet
mechan
exampl
would
expect
rv
bronchiol
older
children
phenotyp
also
character
higher
risk
asthma
predisposit
would
also
higher
degre
share
herit
asthma
strongest
asthma
locu
discov
date
also
found
associ
wheez
earli
year
life
furthermor
interact
locu
earli
wheez
relat
risk
later
asthma
wheez
episod
earli
year
life
much
stronger
risk
factor
asthma
children
risk
variant
children
without
seem
pronounc
episod
trigger
rv
rsv
anoth
asthma
gene
put
role
bronchiol
cadherinrel
famili
member
gene
first
discov
suscept
gene
earli
childhood
asthma
recurr
sever
exacerb
later
suggest
experiment
studi
also
function
rvc
receptor
subsequ
confirm
clinic
copsac
coast
birth
cohort
studi
risk
variant
specif
associ
earli
life
respiratori
episod
trigger
rvc
line
metaanalys
polymorph
relat
bronchiol
associ
nonrsv
bronchiol
like
trigger
rv
associ
rsv
bronchiol
complex
commun
microb
inhabit
part
human
bodi
collect
term
microbiom
immens
microbi
environ
potenti
stimul
develop
immun
system
well
act
diseas
modifi
link
microbiom
suscept
bronchiol
subsequ
asthma
explor
regard
airway
gut
microbiom
mechan
behind
possibl
effect
remain
fulli
understood
come
microbiom
airway
divers
microbiolog
continu
exist
upper
lower
airway
dramat
develop
microbiom
airway
begin
birth
influenc
factor
sibl
daycar
attend
antibiot
prior
infect
figur
specul
whether
low
biomass
compart
obtain
steadi
colon
pattern
time
recent
studi
suggest
certain
microbi
colon
pattern
preval
alreadi
earli
childhood
may
affect
risk
bronchiol
preced
develop
persist
wheez
asthma
furthermor
sever
acut
respiratori
infect
may
modul
type
microbi
commun
airway
independ
rsv
rv
coinfect
time
rsv
rv
may
increas
sever
infect
independ
bacteria
also
shown
antibiot
treatment
acut
wheez
episod
childhood
greatli
decreas
durat
symptom
thu
point
toward
microbi
effect
likewis
studi
infant
demonstr
certain
airway
microbiota
profil
seem
increas
sever
bronchiol
rate
intens
care
use
length
hospit
stay
episod
acut
bronchiol
particularli
high
infant
haemophilusdomin
profil
low
infant
moraxelladomin
profil
although
low
statist
power
especi
appar
children
rsv
bronchiol
found
rv
bronchiol
small
random
trial
children
hospit
rsv
bronchiol
treatment
azithromycin
acut
episod
seem
allevi
subsequ
risk
longterm
respiratori
morbid
microbiom
human
gut
shape
extens
interact
two
bronchiol
episod
may
determin
sever
variou
common
well
distinct
uniqu
pathogen
mechan
typic
result
innat
immun
activ
earli
burst
type
iiii
interferon
occur
rapidli
respiratori
viral
infect
follow
induct
cytokin
includ
alarmin
chemokin
growth
factor
activ
attract
innat
lymphoid
cell
granulocyt
dendrit
cell
monocyt
site
infect
combin
effect
viru
inflammatori
respons
lead
epitheli
cell
apoptosi
necrosi
epitheli
slough
well
mucu
overproduct
howev
rsv
infect
lead
sever
lower
respiratori
tract
infect
primarili
young
children
rv
infect
tend
result
sever
wheez
slightli
older
children
atop
predisposit
particular
order
understand
differ
need
better
insight
immunolog
event
lung
respons
earli
respiratori
infect
initi
respons
mucosa
rsv
infect
strong
induct
antivir
type
type
iii
interferon
interferoninduc
gene
figur
rsv
develop
potent
mechan
evad
innat
interferon
respons
viru
abl
infect
infant
protein
inhibit
suppress
egrf
activ
sever
rsv
bronchiol
associ
weaker
antivir
innat
interferon
respons
data
associ
viru
genom
load
ill
sever
discrep
furthermor
ineffect
inflammatori
adapt
immun
respons
import
factor
contribut
sever
rsv
diseas
birth
immun
system
still
immatur
need
develop
depend
mostli
innat
immun
system
respons
tolllik
receptor
tlr
ligat
maternalderiv
antibodi
time
proinflammatori
innat
immun
respons
promin
antiinflammatori
cytokin
interleukin
il
transform
growth
factor
tgf
beta
prevail
sinc
pregnanc
mother
immun
system
protect
fetu
consequ
helper
cell
skew
cytokin
seem
develop
rather
slowli
young
infant
even
presenc
tlrligat
virus
increas
type
interferon
product
interestingli
cytokin
potent
induc
cell
found
increas
tlrstimul
neonat
cell
neonat
shown
increas
number
th
cell
figur
enhanc
patholog
follow
rsv
infect
often
associ
increas
product
cytokin
promin
neonat
presenc
cytokin
may
contribut
sever
diseas
state
addit
studi
neonat
mice
shown
spontan
earli
wave
innat
cytokin
th
skew
cytokin
recruit
innat
lymphoid
cell
ilc
lung
reach
maximum
day
birth
therefor
agespecif
event
neonat
lung
seem
natur
support
initi
develop
th
immun
respons
combin
yet
ineffect
activ
innat
immun
upregul
young
infant
drive
mucu
hyperproduct
promot
sever
patholog
earli
rsv
infect
addit
bcell
function
yet
develop
young
infant
month
age
take
time
gener
suffici
sustain
antibodi
product
earli
phase
babi
still
reli
matern
antibodi
babi
born
mother
high
circul
neutral
antibodi
better
protect
sever
diseas
notion
led
idea
develop
vaccin
rsv
target
pregnant
mother
instead
young
children
thu
vaccin
mother
children
would
provid
increas
transfer
protect
matern
antibodi
rsv
rhinovirus
also
directli
target
airway
epitheli
cell
rv
type
frequent
caus
lower
respiratori
tract
infect
rv
type
c
particular
link
sever
wheez
infect
children
increas
risk
sever
rv
infect
wheez
young
children
strong
famili
histori
allergi
asthma
may
explain
partial
defect
mucos
antivir
innat
interferon
respons
due
potenti
earli
allerg
airway
inflamm
figur
airway
mucosa
asthmat
allerg
airway
inflamm
shown
associ
reduc
type
type
iii
interferon
respons
understand
particularli
high
pathogen
potenti
rvc
import
note
recent
identifi
uniqu
receptor
rvc
interestingli
polymorph
gene
result
higher
express
epitheli
surfac
associ
increas
risk
childhood
asthma
rvc
also
evolv
specif
molecular
tool
reduc
express
downstream
signal
airway
epitheli
cell
may
possibl
explain
sever
cours
respiratori
rvc
infect
addit
rv
infect
airway
epitheli
cell
strong
induc
type
innat
cytokin
subsequ
initi
boost
type
immun
lung
via
innat
lymphoid
cell
ilc
th
cell
figur
surprisingli
induct
innat
cytokin
rv
infect
stronger
airway
epitheli
cell
asthmat
compar
healthi
control
also
induct
type
innat
cytokin
may
pronounc
earli
childhood
compar
adult
mice
human
rhinoviru
infect
neonat
mice
show
pronounc
express
mucu
secret
airway
hyperrespons
process
may
boost
coincid
earli
spontan
wave
type
cytokin
cell
develop
lung
neonat
mice
overal
although
rv
infect
link
induct
milder
epitheli
inflamm
rsv
infect
tend
reduc
type
ifn
express
caus
inflamm
th
cell
characterist
disrupt
tight
junction
express
high
cytokin
level
promot
bronchospasm
edema
mucu
product
lead
airway
obstruct
wheez
support
treatment
oxygen
nasal
suction
mechan
ventil
hydrat
high
flow
oxygen
therapi
use
nasal
cannula
shown
promis
result
conflict
inform
across
clinic
guidelin
role
nebul
hyperton
salin
acut
manag
bronchiol
current
guidelin
recommend
bronchodil
overal
corticosteroid
see
detail
nebul
epinephrin
antibiot
recommend
current
frustrat
exist
treatment
modal
high
use
bronchodil
antibiot
corticosteroid
major
previou
trial
base
virusspecif
data
research
requir
order
direct
focu
person
manag
plan
treatment
acut
bronchiol
palivizumab
immunoprophylaxi
palivizumab
human
monoclon
antibodi
rsv
f
glycoprotein
decreas
risk
hospit
due
sever
rsv
ill
among
preterm
infant
reduct
chronic
lung
diseas
reduct
hemodynam
signific
congenit
heart
diseas
reduct
interestingli
palivizumab
effect
reduc
recurr
wheez
follow
hospit
due
rsv
asthma
ribavirin
convinc
data
support
ribavirin
treatment
sever
rsv
infect
lack
toxic
remain
concern
therefor
ribavirin
recommend
current
us
guidelin
new
treatment
current
approxim
rsv
vaccin
antibodi
preclin
develop
anoth
clinic
develop
agent
target
inhibit
attach
rv
cell
uncoat
viral
rna
clinic
applic
continu
question
due
advers
event
pleconaril
vapendavir
drug
resist
amantadin
rimantadin
prednisolon
two
separ
random
trial
oral
corticosteroid
prednisolon
shown
increas
time
physicianconfirm
relaps
within
follow
year
initi
asthma
control
medic
within
follow
year
firsttim
wheez
children
rv
etiolog
result
point
earli
system
antiinflammatori
control
target
preexist
andor
virusinduc
airway
inflammatori
respons
could
significantli
affect
natur
cours
asthma
interestingli
wheez
children
high
rv
genom
load
treat
placebo
develop
new
physicianconfirm
wheez
episod
within
day
initi
asthma
control
medic
within
month
conclus
accord
hypothesi
regard
variou
entiti
bronchiol
emphas
effect
treatment
bronchiol
administ
person
base
current
practic
includ
variou
viral
etiolog
factor
believ
exist
treatment
method
beta
agonist
corticosteroid
effect
given
assumpt
intend
distinct
rvaffect
highrisk
group
patient
howev
urgent
unmet
need
new
guidelin
would
recogn
discrep
clinician
understand
common
bronchiol
sever
acut
bronchiol
experienc
earli
childhood
associ
increas
risk
asthma
may
persist
earli
adulthood
remain
elucid
whether
bronchiol
caus
lung
injuri
result
subsequ
wheez
episod
asthma
develop
whether
inher
predisposit
acut
bronchiol
latter
asthma
bronchiol
earli
marker
predisposit
regardless
possibl
underli
lung
morbid
major
viral
caus
acut
bronchiolitisfirst
wheez
rsv
rv
seem
differ
cours
postbronchiol
asthma
sequela
sever
observ
studi
report
associ
rsvbronchiol
subsequ
asthma
develop
exampl
accord
populationbas
studi
n
tucson
arizona
birth
cohort
studi
n
australia
rsvinduc
lower
respiratori
infectionbronchiol
earli
life
modestli
associ
recurr
wheezingdoctordiagnos
asthma
schoolag
odd
ratio
atopi
similar
number
also
found
preterm
infant
small
cohort
studi
sweden
shown
associ
rsvbronchiol
later
allerg
sensit
well
asthma
age
rsv
children
allerg
asthma
compar
control
group
respect
address
potenti
causal
rsv
infect
subsequ
asthma
prospect
studi
rsvimmunoprophylaxi
perform
two
recent
random
control
trial
show
preterm
infant
palivizumab
antirsv
monoclon
antibodi
decreas
parentreport
recurr
wheez
similar
incid
physiciandiagnos
asthma
age
year
found
longterm
effect
rsv
prophylaxi
appear
less
like
infant
atop
famili
histori
result
clearli
indic
rsvinfect
causal
asthma
atopi
develop
one
potenti
explan
result
children
rsv
infect
subsequ
asthma
develop
may
share
common
genet
vulner
andor
environment
exposur
predispos
diseas
jartti
et
al
contrast
rsv
bronchiol
atopi
clearli
associ
childhood
asthma
develop
rvinduc
earli
wheez
highrisk
parent
atopi
asthma
birth
cohort
studi
wisconsin
unit
state
australia
shown
young
children
suffer
rvinduc
wheez
episod
high
risk
schoolag
asthma
odd
ratio
rv
vs
rsv
vs
risk
especi
high
children
sensitiz
age
younger
year
recent
studi
hospit
children
show
similar
result
rvinduc
sever
first
wheez
episod
age
less
year
risk
factor
odd
ratio
atop
asthma
schoolag
along
earli
sensit
eczema
odd
ratio
respect
rsv
associ
neither
atop
nonatop
asthma
therefor
data
highrisk
birth
cohort
suggest
atop
airway
increas
suscept
asthma
develop
rvinduc
bronchiol
primari
prevent
strategi
asthma
aim
reduc
incid
diseas
identifi
individu
risk
reduc
exposur
potenti
risk
factor
first
hygien
hypothesi
evolv
cover
environment
microbi
burden
gener
howev
due
recent
find
scope
hygien
hypothesi
enlarg
cover
environment
biodivers
gener
thu
rapid
urban
pollut
climat
chang
lead
loss
biodivers
promot
chronic
noncommunic
ill
asthma
allergi
diabet
obes
cancer
wherea
frequent
contact
anim
lipopolysaccharid
present
eat
touch
breath
prevent
atopi
allerg
rhiniti
sometim
asthma
second
condit
pregnanc
import
matern
longchain
polyunsatur
fatti
acid
lcpufa
vitamin
supplement
third
trimest
pregnanc
may
reduc
risk
persist
wheezeasthma
respiratori
infect
offspr
figur
secondari
prevent
strategi
asthma
aim
avoid
develop
allerg
diseaseasthma
alreadi
sensit
wheez
subject
thu
far
allergen
immunotherapi
remain
treatment
avail
modifi
cours
allerg
diseas
howev
although
recent
studi
grass
pollen
immunotherapi
shown
reduc
asthmalik
symptom
children
decreas
develop
asthma
interestingli
though
system
antiinflammatori
treatment
first
rvinduc
sever
wheez
episod
markedli
decreas
subsequ
risk
asthma
figur
see
section
also
yearround
preseason
treatment
omalizumab
shown
elimin
season
peak
asthma
exacerb
associ
rv
infect
addit
reduct
allerg
inflamm
prevent
ige
bind
receptor
omalizumab
also
enhanc
respons
thu
argu
omalizumab
may
improv
antivir
respons
rsv
immunoprophylaxi
palivizumab
also
shown
reduc
recurr
wheez
see
section
develop
rv
vaccin
promis
result
seen
crossreact
recombin
capsid
protein
mous
model
nonspecif
antivir
approach
reduc
asthma
includ
strategi
aim
enhanc
patient
resist
multipl
respiratori
virus
administr
interferon
immunostimulatori
molecul
strategi
microbi
other
promot
healthi
epitheli
barrier
develop
mucos
immun
respons
better
resist
viral
infect
might
also
help
prevent
develop
asthma
well
bacteri
lysat
may
reduc
recurr
wheez
increas
antivir
activ
howev
level
evid
still
remain
low
f
g
u
r
e
major
factor
influenc
asthma
risk
young
children
suffer
bronchiol
rv
rhinoviru
rsv
respiratori
syncyti
viru
lcpufa
longchain
polyunsatur
fatti
acid
go
forward
import
identifi
patient
high
risk
asthma
find
specif
primari
secondari
prevent
strategi
individu
patient
figur
exampl
sensit
eczema
first
sever
wheez
caus
rv
appear
predict
atop
asthma
first
sever
wheez
age
rvrsvneg
etiolog
andor
associ
parent
smoke
appear
predict
nonatop
asthma
conclus
new
insight
viral
virul
person
risk
factor
genet
allergi
antivir
immun
environment
exposur
farm
urban
microb
nutrit
provid
hope
futur
might
abl
reduc
occurr
childhood
asthma
figur
clinic
pathophysiolog
three
main
cluster
patient
identifi
among
children
suffer
sever
bronchiolitisfirst
wheez
episod
figur
rsvinduc
bronchiol
character
young
age
patient
mechan
obstruct
airway
due
mucu
cell
debri
treatment
rsvinduc
bronchiol
prophylact
rsvspecif
monoclon
antibodi
avail
decreas
risk
recurr
wheez
rvinduc
wheez
associ
atop
predisposit
high
risk
asthma
may
revers
system
corticosteroid
patient
sever
first
episod
rv
suscept
thu
serv
import
earli
marker
asthmapron
children
wheez
due
virus
like
less
frequent
sever
clinic
import
distinguish
three
partial
overlap
patient
group
like
respond
differ
treatment
first
sever
episod
bronchiol
wheez
less
child
appear
critic
event
import
opportun
design
secondari
prevent
strategi
asthma
thu
bronchiol
simpli
diagnos
use
certain
cutoff
age
instead
viral
etiolog
use
differenti
factor
nomenclatur
suggest
rsvinduc
bronchiol
rvinduc
first
wheez
episod
better
distinguish
condit
author
thank
mr
agnieszka
sierakowska
assist
prepar
illustr
miss
anna
eskola
edit
languag
articl
author
declar
conflict
interest
author
particip
draft
write
manuscript
grant
agenc
cover
cost
play
role
manuscript
prepar
import
distinguish
patient
group
sinc
like
respond
differ
treatment
also
first
episod
sever
bronchiol
wheez
children
appear
critic
event
opportun
design
secondari
prevent
strategi
asthma
moab
monoclon
antibodi
oc
oral
corticosteroid
th
helper
cell
